Jennison Associates LLC Ligand Pharmaceuticals Inc Transaction History

Jennison Associates LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 05, 2021	SELL	$80.55 - $106.05 $5.75 Million - $7.57 Million	-71,347 Closed	0 $0
Q3 2020 Nov 04, 2020	BUY	$89.56 - $126.72 $106,576 - $150,796	1,190 Added 1.7%	71,347 $6.8 Million
Q2 2020 Aug 06, 2020	SELL	$68.28 - $123.65 $1.07 Million - $1.95 Million	-15,741 Reduced 18.33%	70,157 $7.85 Million
Q1 2020 May 06, 2020	BUY	$63.37 - $107.88 $249,741 - $425,155	3,941 Added 4.81%	85,898 $6.25 Million
Q4 2019 Feb 07, 2020	SELL	$96.94 - $113.59 $145,603 - $170,612	-1,502 Reduced 1.8%	81,957 $8.55 Million
Q3 2019 Nov 08, 2019	SELL	$86.25 - $120.16 $10.9 Million - $15.2 Million	-126,868 Reduced 60.32%	83,459 $8.31 Million
Q2 2019 Aug 06, 2019	SELL	$107.38 - $129.34 $1.26 Million - $1.52 Million	-11,732 Reduced 5.28%	210,327 $0
Q1 2019 May 10, 2019	BUY	$105.93 - $142.47 $3.17 Million - $4.26 Million	29,892 Added 15.56%	222,059 $27.9 Million
Q4 2018 Feb 06, 2019	BUY	$128.36 - $272.13 $24.7 Million - $52.3 Million	192,167 New	192,167 $26.1 Million

257

18.2M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.88B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Jennison Associates LLC with notifications on news.